Anlotinib Plus S-1 for Patients with EGFR Mutation-Negative Advanced Squamous Cell Lung Cancer with PS Scores of 2–3 After Progression of Second-Line or Later-Line Treatment

OBJECTIVE: The study aimed to analyze the efficacy and safety of combination regimen of anlotinib and S-1 for Chinese patients with EGFR mutation-negative advanced squamous cell lung cancer (SqCLC) with poor performance status (PS,2–3) after progression of second-line or later-line chemotherapy. MET...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Manag Res
Autors principals: Xie, Xiao-Hong, Wang, Fei, Lin, Xin-Qing, Qin, Yin-Yin, Xie, Zhan-Hong, Zhang, Jie-Xia, Ouyang, Ming, Zhou, Cheng-Zhi
Format: Artigo
Idioma:Inglês
Publicat: Dove 2020
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7735716/
https://ncbi.nlm.nih.gov/pubmed/33328765
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S278068
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars